Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
View stock
VS
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
View stock

Stock highlights

Stock comparison highlights
Stock name
Merck KGaAAbbVie
Last price
€140.78$283.49
Currency
EUR
USD
€60B$485B
25.2877.51
€5.45$3.54
0.810.28
€2.20$6.83
1.60%2.52%
Sector
HealthHealth
Employees
62,13657,000
Ticker
€MRK$ABBV
Primary listing
XETRANYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in €MRK or $ABBV on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.